KEYS:NYSEKeysight Technologies Inc. Analysis
Data as of 2026-04-12 - not real-time
$324.18
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Keysight Technologies (KEYS) is trading at $324.18, well above its DCF‑derived fair value of $215.58, indicating a substantial premium. The stock sits near its 52‑week high of $325.55 and just above the 20‑day SMA of $291.88, confirming strong recent price momentum. Technical gauges are bullish, with the MACD line ($11.29) crossing above its signal ($8.27) and a histogram of $3.02, while the RSI sits at 69.6, flirting with overbought territory. Volume trends are weakening, however, as the recent volume is decreasing despite the price rally, hinting at a potential slowdown in buying pressure. The company posted a 23.3% revenue growth year‑over‑year, delivering a solid 61.9% gross margin and a 16.3% operating margin, underscoring its high‑margin business model. Cash on hand ($2.18 bn) comfortably exceeds total debt ($2.77 bn) and the debt‑to‑equity ratio of 44.7% remains manageable given the strong operating cash flow ($1.47 bn).
Nevertheless, the forward PE of 31.6, while lower than the trailing PE of 57.2, still exceeds the industry average PE of 33.9, suggesting the market has priced in continued growth. The beta of roughly 1.15–1.67 and a 30‑day volatility of 46% point to heightened price sensitivity, especially in a market currently in an “Extreme Greed” phase (fear‑greed index 87). Recent guidance for Q2 revenue of $1.69‑$1.71 bn and the rollout of AI‑centric, 6G and satellite test solutions signal a robust growth pipeline. Analysts maintain a “Buy” consensus with a median price target of $310, yet the current upside is limited to about –5.7% from the DCF perspective. The lack of dividend payout eliminates yield‑focused appeal, positioning the stock primarily as a growth play. In this context, the stock’s upside appears constrained in the short run, while its long‑term trajectory hinges on the successful capture of AI‑driven test market share.
Nevertheless, the forward PE of 31.6, while lower than the trailing PE of 57.2, still exceeds the industry average PE of 33.9, suggesting the market has priced in continued growth. The beta of roughly 1.15–1.67 and a 30‑day volatility of 46% point to heightened price sensitivity, especially in a market currently in an “Extreme Greed” phase (fear‑greed index 87). Recent guidance for Q2 revenue of $1.69‑$1.71 bn and the rollout of AI‑centric, 6G and satellite test solutions signal a robust growth pipeline. Analysts maintain a “Buy” consensus with a median price target of $310, yet the current upside is limited to about –5.7% from the DCF perspective. The lack of dividend payout eliminates yield‑focused appeal, positioning the stock primarily as a growth play. In this context, the stock’s upside appears constrained in the short run, while its long‑term trajectory hinges on the successful capture of AI‑driven test market share.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and RSI near overbought suggest limited upside
- Price is at resistance near 52‑week high
- Decreasing volume may signal weakening momentum
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strong revenue growth and AI/6G product pipeline
- Forward PE still high relative to industry
- Current price above DCF fair value limiting upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Secular demand for AI data‑center testing solutions
- High gross and operating margins sustain profitability
- Robust cash position and manageable debt support growth investments
Key Metrics & Analysis
Financial Health
Revenue Growth23.30%
Profit Margin16.95%
P/E Ratio57.2
ROE17.22%
ROA5.82%
Debt/Equity44.67
P/B Ratio9.0
Op. Cash Flow$1.5B
Free Cash Flow$1.1B
Industry P/E33.9
Technical Analysis
TrendBullish
RSI69.6
Support$266.47
Resistance$325.55
MA 20$291.88
MA 50$271.98
MA 200$203.10
MACDBullish
VolumeDecreasing
Fear & Greed Index87.09
Valuation
Fair Value$215.58
Target Price$305.77
Upside/Downside-5.68%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.67
Volatility45.99%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.